ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction
|
|
- Randolph Watts
- 6 years ago
- Views:
Transcription
1 European Heart Journal (2003) 24, ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction Paul W. Armstrong a *, Galen Wagner b, Shaun G. Goodman c, Frans Van de Werf d, Christopher Granger b, Lars Wallentin e, Yuling Fu a, for the ASSENT 3 Investigators a University of Alberta, Edmonton, Canada b Duke Clinical Research Institute, Durham, NC, USA c University of Toronto, Ontario, Canada d University Hospital Gasthuisberg, Leuven, Belgium e University Hospital, Uppsala, Sweden Received 6 February 2003; received in revised form 9 May 2003; accepted 4 June 2003 This paper was guest edited by Prof. Peter L. Thompson, University of Western Australia, Perth, Australia KEYWORDS Acute myocardial infarction; Fibrinolysis; ST segment resolution Aims ASSENT 3 (Assessment of the Safety and Efficacy of a New Thrombolytic) demonstrated that the bolus fibrinolytic tenecteplase (TNK), combined with enoxaparin (ENOX) or abciximab (ABCX), substantially reduced ischemic complications of acute myocardial infarction as compared with unfractionated heparin (UH). We compared ST resolution in each of the three treatment regimens in order to evaluate the speed, extent and stability of ST segment resolution and its relationship to the primary composite endpoint(s) of the trial. Methods and results We evaluated ST segment shift and its subsequent resolution i.e. complete ( 70%), partial (<70 30%) and no resolution (<30%) in 4,304 patients 60 and 180 min after treatment. Sixty minutes after therapy there was a trend for both half-dose TNK/ABCX and TNK/UH to have more frequent complete ST resolution (P=0.072) than TNK/ENOX. Pair-wise comparison at 60 min revealed that patients receiving TNK/ABCX had significantly more complete ST resolution than TNK/ENOX (P=0.026). Further ST resolution had occurred 180 min after treatment: complete ST resolution was greater with TNK/ABCX (59.2%) than the TNK/heparin (50.8%) and TNK/enoxaparin (50.8%) (P<0.001). In the TNK/ENOX group achieving complete ST resolution by 180 min, in-hospital reinfarction was 1.9% vs 4.2% for TNK/UH (P=0.015) representing a 2.3% absolute and 55% relative reduction in reinfarction. Thirty day and one year mortality was greatest amongst those patients with <30% ST segment resolution in the TNK/ABCX group. Conclusions More rapid and complete ST resolution occurs with half-dose TNK/ABCX whereas less reinfarction occurs amongst those patients with 70% ST resolution receiving either TNK/ABCX or TNK/ENOX. These data highlight two potentially complementary mechanisms of clinical benefit associated with different pharmacologic regimens in acute myocardial infarction, i.e. more rapid versus more stable coronary patency Published by Elsevier Ltd on behalf of The European Society of Cardiology. * Corresponding author. Paul W. Armstrong, MD, 2 51 Medical Sciences Building, University of Alberta, Edmonton, Alberta, Canada T6G 2H7. Tel.: ; fax: address: paul.armstrong@ualberta.ca (P.W. Armstrong) X/03/$ - see front matter 2003 Published by Elsevier Ltd on behalf of The European Society of Cardiology. doi: /s x(03)
2 1516 P.W. Armstrong et al. Introduction Recently the ASSENT 3 (Assessment of the Safety and Efficacy of a New Thrombolytic) trial demonstrated that when the bolus fibrinolytic tenecteplase (TNK) was combined with enoxaparin (ENOX) or abciximab (ABCX), it substantially reduced the frequency of ischaemic complications of acute myocardial infarction as compared with conventional unfractionated heparin (UH). 1 This intermediate-sized trial was not primarily designed as a mortality trial but rather aimed at evaluation of treatment effects on a clinical composite end-point of 30-day death, reinfarction and refractory ischaemia. Given the prior work establishing the relationship between ST segment resolution and clinical outcomes, a systematic, prospective electrocardiographic analysis of the extent of ST segment resolution at 60 and 180 min after treatment was incorporated into the study in order to provide mechanistic insight into these end-points. 2,3 Recent availability of one-year mortality data provides additional opportunity for the evaluation of longer-term results. Our objectives were to compare the speed, extent and stability of ST segment resolution in each of the three treatment regimens and to evaluate their relationship to the primary composite endpoint(s) of the trial. Methods The ASSENT 3 trial has previously been described in detail. 1 Briefly, 6095 patients with acute myocardial infarction were randomly assigned to one of three regimens: full dose TNK and ENOX for a maximum of 7 days, half dose TNK with weightadjusted low dose unfractionated heparin and a 12-h infusion of ABCX or full dose TNK with weight-adjusted unfractionated heparin for 48 h. ECG criteria for admission were ST segment elevation 0.1 mv in at least two limb leads or 0.2 mv in two contiguous precordial leads or the presence of presumed new left bundle branch block. The ASSENT 3 ECG substudy consisted of the entire study population and pre-specified that a 12-lead ECG be recorded at baseline and again at 60 and 180 min after treatment. The ST segment measurements were evaluated centrally without reader knowledge of the treatment assignment or clinical outcome at the ECG core laboratories (Canadian VIGOUR Centre, University of Alberta, Edmonton, Canadian Heart Research Center, Toronto, and Duke Clinical Research Institute). To minimize confounding factors influencing the accuracy of the assessment of ST segment resolution, patients were excluded (Fig. 1) from this analysis if they were: (1) missing baseline, 60 or 180 min tracings (n=463); (2) without the protocol-defined amount of ST elevation on baseline ECG (n=481); or (3) had left bundle branch block (LBBB), paced rhythm, ventricular rhythm, or poor quality ECG s. Of the 463 patients with missing ECG s, 65 died within 30 days and of these, 62 died prior to the recording of the 180 min ECG. Of the 481 patients without the required ST elevation, 175 had no CK elevation and their 30-day mortality was 3.4% whereas a mortality of 7.2% for the remaining 306 patients with elevated CK was observed. Of the 847 patients with confounding ECG factors, 740 had poor quality ECG s and had a 30 day mortality of 8.4% whereas the 107 patients with either LBBB, paced rhythm or ventricular rhythm had a 30 day mortality of 13.1%. One-year mortality tracked the 30-day results and is also demonstrated in Fig. 1 Hence, the final ECG substudy group consisted of 4598 patients of whom 4304 had all three ECG s. Electrocardiographic (ECG) analysis The amount of ST segment elevation was measured manually at the J point using a hand-held caliper from leads I, avl and V1 to V6 for anterior myocardial infarction and leads II, III, avf, V5 and V6 for inferior MI. For the total ST segment deviation the sum of ST segment depression in leads II, III and avf for anterior and Fig. 1 Disposition of patients as well as their 30-day/1 year mortality.
3 ST resolution in ASSENT Table 1 that in leads V1 to V4 for inferior myocardial infarction were added. The resolution of ST segment elevation (or total deviation) at 60 min and 180 min was stratified into three categories based on Schroeder s method (2): complete resolution was defined as resolution of the initial sum of ST segment elevation 70%, partial resolution was defined as ST segment resolution <70% to 30%, and no resolution was defined as ST segment resolution <30%. In addition to this classification based primarily on the extent of ST resolution, patients were also categorized according to treatment assignment and on the relationship to the principal efficacy endpoints of ASSENT 3. Statistical analysis Descriptive statistics were summarized as medians with 25th and 75th percentiles for continuous variables and the Kruskal Wallis test was used for comparisons among treatment regimens. For categorical variables, the data were summarized in percentages and Fisher s exact test or the Chi-square test was used to assess group differences. Multivariate logistic regression analysis was used to assess the effect of baseline characteristics and extent of ST segment resolution on 30 day and one year mortality. 4 Variables examined included age, gender, presence of hypertension or diabetes, current smoking, previous MI, previous coronary artery bypass grafting (CABG) or previous PCI, systolic blood pressure, heart rate, index MI location, Killip class at presentation, time from symptom onset to treatment, and treatment assigned. All tests were 2-sided, with a 5% level of significance. All analyses were performed using SPSS (Chicago, Illinois, Version 11). Results Baseline characteristics according to treatment assignment In Table 1 the baseline characteristics of the patients in the ECG substudy are shown according to treatment assignment. As was the case in the overall study, patient characteristics were similar across the three treatment groups. The overall median time intervals (25th and 75th percentiles) from the start of bolus TNK to the acquisition of 60 min and 180 min ECG were 61 min (55, 68), and 183 min (174, 195), respectively. There were no differences in time to acquisition of ECG s at either of these time points among the three treatment groups: hence the TNK/ENOX n=1444 ½ TNK/ABCX n=1445 TNK/UH n=1415 Age (median) 60 (52, 69) 59 (51, 70) 60 (51, 70) Age >75 years % Female % Weight (kg) 77 (70, 88) 78 (68, 88) 78 (69, 88) Time from onset of symptoms to randomization (h) 2.3 (1.6, 3.5) 2.5 (1.6, 3.5) 2.5 (1.7, 3.6) Killip class >I Systolic blood pressure (mmhg) 133 (120, 150) 132 (120, 150) 132 (119, 150) Anterior infarct location % Heart rate (bpm) 73 (62, 85) 73 (63, 84) 72 (62, 84) Hypertension % Diabetes % Previous myocardial infarction % Prior CABG % Prior PCI % Current smoker % median times were 61 (55,68) and 183 (174,195) min for TNK/ENOX; 60 (52,69) and 182 (173,195) min for TNK/ ABCX, and 61 (55,69) and 183(175,194) for TNK/UH respectively. In Fig. 2a and b the data according to the extent of ST resolution at 60 and 180 min are shown for each of the three treatment groups. By 60 min there was a trend for both half-dose TNK/ABCX and TNK/UH to have more frequent complete, i.e. 70% ST resolution (P=0.072) than TNK/ENOX. Pair wise comparison at 60 min revealed that patients receiving TNK/ABCX had significantly more complete ST resolution than the TNK/ENOX group (P=0.026). Further significant complete ST resolution had occurred after 180 min had elapsed (Fig. 2b) in each of the three treatment groups: the extent of ST resolution was greater however in the TNK/ABCX arm than that evident in either of the two TNK heparin arms (P<0.001). These changes are further evident in Fig. 3 where the ST segment resolution data at both 60 and 180 min are restricted to those patients who had ECG s at both these time points as a basis for comparison with their baseline measures. The incremental improvement between 60 and 180 min was highest in patients receiving TNK/ABCX and significantly greater than that seen with TNK/UH (25.7% vs 19.1%; P=0.002): a trend for a similar incremental improvement in ST resolution between 60 and 180 min was also evident for TNK/ENOX vs TNK/UH (23.5% vs 19.1%; P=0.069). In order to track the stability of ST segment resolution the evolution of ST segment change between 60 and 180 min is shown in Fig. 4 according to both treatment group and initial extent of ST resolution at 60 min. As is evident in Fig. 4a (upper right panel) the transition from 34.5% to 50.8% of TNK/UH patients with complete ST resolution reflects that mixture of 756 (53%) patients who had already achieved ST resolution at 60 min, coupled with the 415 (29.3%) patients who had had partial resolution at 60 min and the 243 (17.2%) patients without initial ST resolution. In the lower right panel of Fig. 4a, the composition of those patients who had <30% ST resolution at 180 min is highlighted. Interestingly,
4 1518 P.W. Armstrong et al. Fig. 2 (a) Distribution of 60 minutes ST segment resolution according to treatment assignment, P=0.072 for trend comparison. (b) Distribution of 180 min ST segment resolution according to treatment assignment, P<0.001 for trend comparison. 29 (11.2%) of those with complete and 48(19.0%) of those with partial ST resolution at 60 min showed deterioration by 180 min with resultant <30% ST resolution. The ENOX group proved to be intermediate and those receiving TNK/ABCX showed the least deterioration or greatest preservation of their initial ST resolution evident at 60 min (Fig. 4b, 4c, respectively). A similar pattern was observed between 60 and 180 min for those patients with partial ST segment resolution initially as compared with those with complete or <30% ST resolution. In Table 2a and Table 2b the composite efficacy endpoints are presented by treatment assignment and categorized according to the extent of ST resolution evident at 60 and 180 min, respectively. By 60 min a clear advantage for a reduction in the composite efficacy endpoint was evident in patients with >70% ST resolution treated with TNK/ABCX vs those receiving TNK/UH. This pattern was also evident for reinfarction. The extent of ST resolution appeared to have little relationship to the benefit afforded by TNK/ENOX as compared with TNK/UH even after adjustment for key baseline characteristics. For patients with <30% ST resolution, mortality was lowest in those receiving TNK/ENOX, especially as compared with TNK/ABCX. At 180 min the findings seen at 60 min
5 ST resolution in ASSENT Fig. 3 Distribution of 60 and 180 min ST segment resolution of 4304 patients who had ECG s at both 60 and 180 min according to treatment assignment, P=0.081 and P<0.001 for trend comparison, respectively. with TNK/ABCX and TNK/ENOX became more pronounced in patients with more than 70% resolution of ST segments i.e. a significant reduction in both the composite endpoint and in-hospital reinfarction as compared with TNK/ UH. In the TNK/ENOX group achieving complete ST resolution by 180 min, in-hospital reinfarction was 1.9% vs 4.2% for TNK/UH (P=0.015) representing a 2.3% absolute and 55% relative reduction in reinfarction. Amongst patients with <30% ST resolution, thirty-day and one year mortality was lowest amongst those in the TNK/ENOX arm and highest for those receiving TNK/ABCX. Moreover within the TNK/ABCX group those patients with less than 30% ST segment resolution had a significantly longer median time from symptom onset to treatment (3.04 h) as compared to those with partial (2.9 h) or complete ST resolution (2.75 h) (P=0.006). It is noteworthy that examination across the three treatment groups amongst all patients without ST segment resolution at 180 min revealed that the median time (h) from symptom onset to treatment was significantly longer for abciximab treated patients (3.04) as compared to those treated with enoxaparin (2.5 h) or those with unfractionated heparin (2.67) (P<0.001). These patterns were also evident from analysis performed at the 60-min data point. Discussion These data derived from a systematic analysis of ST segment resolution in over 4000 patients provide new mechanistic insights into the treatment effect of the two experimental arms within the ASSENT 3 study, i.e. TNK/ ENOX and TNK/ABCX as compared with the control arm of TNK/UH. A key finding from our study is the demonstration of more rapid and complete ST segment resolution when half-dose TNK is combined with abciximab: although this was already evident 60 min after commencement of therapy it became more fully expressed and amplified at 180 min. Further insight and support for these findings is derived from the lesser tendency of patients receiving TNK/ABCX to demonstrate deterioration in complete ST resolution by 180 min once it had been achieved at 60 min following treatment. Importantly, this greater treatment effect following TNK/ABCX on an established electrocardiographic surrogate for enhanced myocardial perfusion is in concert with the lesser need for urgent revascularization demonstrated for this treatment group in the overall ASSENT 3 study. 1 It is noteworthy however that the highest mortality at 30 days and one year occurred in those patients showing failure of ST segment resolution following treatment with TNK/ABCX. The basis for this finding is unclear but could signal identification of patients with more complex thrombotic obstruction resistant to a more potent pharmacologic reperfusion regimen thereby resulting in a worse prognosis. Another potentially contributing factor was the longer time from symptom onset to treatment in this group. Interestingly, the treatment arm in ASSENT 3 that achieved the best balance between efficacy and safety, i.e. TNK/ENOX, had the least number of patients achieving complete ST resolution at 60 min: by 180 min however the ST segment resolution results in this treatment group were comparable to those in the reference arm receiving TNK/UH. These findings are consistent with those derived from the HART-2 angiographic study where no early coronary patency advantage was demonstrable with the combination of enoxaparin and accelerated
6 1520 P.W. Armstrong et al. Fig. 4 (a c) Evolution of ST segment resolution from 60 to 180 min for TNK/UH (a), TNK/ENOX (b) and TNK/ABCX (c). Patients with complete ST resolution are shown as clear, those with partial ST resolution are hatched and those with <30% ST resolution are gray. The left panel in each figure depicts the extent of ST resolution evident at 60 min. The transition from the left to the middle panel represents the evolution of ST segment resolution between 60 and 180 min. All percentages are derived from the sample size shown in the title. The composition of actual patient numbers with complete ST resolution by 180 min and for those with <30% ST resolution is outlined in the small circles in the extreme right upper and lower panels of each figure. Hence for the 50.8% of TNK/UH patients in Fig. 4a who achieved complete ST resolution at 180 min (upper right panel), 756 of these had achieved complete ST resolution by 60 min, 415 had initially 30 70% ST resolution and 243 had <30% ST resolution at 60 min.
7 ST resolution in ASSENT Table 2a All patients Efficacy endpoints by 60 min ST segment resolution according to treatment assignment TNK/ENOX 1444 ½ TNK/ABCX 1445 TNK/UH % resolution 30-day mortality, in-hospital remi, or refractory ischaemia 9.2 (41/444) 6.2 (32/513) a 11.9 (58/488) In-hospital reinfarction 2.5 (11/444) 2.1 (11/513) a 4.9 (24/488) day mortality 4.1 (18/444) 2.5 (13/513) 2.0 (10/488) year mortality 6.2 (27/439) 5.4 (27/503) 3.6 (17/471) P for trend 30 70% resolution 30-day mortality, in-hospital remi, or refractory ischaemia 11.1 (54/487) a 10.1 (46/457) a 16.0 (71/445) In-hospital reinfarction 3.1 (15/487) 2.6 (12/457) 5.2 (23/445) day mortality 3.5 (17/487) 4.6 (21/457) 5.4 (24/445) year mortality 7.3 (35/477) 6.9 (31/450) 8.2 (36/437) <30% resolution 30-day mortality, in-hospital remi, or refractory ischaemia 10.7 (55/513) a 13.3 (63/475) 16.4 (79/482) In-hospital reinfarction 2.7 (14/513) 2.5 (12/475) 2.7 (13/482) day mortality 4.3 (22/513) b 8.8 (42/475) 5.8 (28/482) year mortality 7.2 (36/501) 10.7 (50/467) 7.8 (36/462) a Denotes P for pair-wise comparisons between TNK/UH versus TNK/ENOX or ½ TNK/ABCX. b Denotes P=0.004 for comparison between TNK/ENOX and ½ TNK/ABCX. Table 2b All patients Efficacy endpoints by 180 min ST segment resolution according to treatment assignment TNK/ENOX 1444 ½ TNK/ABCX 1445 TNK/UH 1415 P for trend 70% resolution 30-day mortality, in-hospital remi, or refractory ischaemia 8.3 (61/734) a 7.0 (60/856) a 12.4 (89/719) In-hospital reinfarction 1.9 (14/734) a 2.2 (19/856) a 4.2 (30/719) day mortality 3.7 (27/734) 2.9 (25/856) 3.6 (26/719) year mortality 6.5 (47/722) 5.6 (47/840) 5.3 (37/700) % resolution 30-day mortality, in-hospital remi, or refractory ischaemia 10.6 (50/471) 11.2 (48/427) 14.8 (65/438) In-hospital reinfarction 2.8 (13/471) 2.6 (11/427) 3.4 (15/438) day mortality 4.2 (20/471) 5.9 (25/427) 3.2 (14/438) year mortality 7.0 (32/459) 7.8 (33/422) 5.2 (22/420) <30% resolution 30-day mortality, in-hospital remi, or refractory ischaemia 16.3 (39/239) 20.4 (33/162) 20.9 (54/258) In-hospital reinfarction 5.4 (13/239) 3.1 (5/162) 5.8 (15/258) day mortality 4.2 (10/239) b 16.0 (26/162) a 8.5 (22/258) < year mortality 8.1 (19/236) b 17.7 (28/158) 12.0 (30/250) a Denotes P for pair-wise comparisons between TNK/UH versus TNK/ENOX or ½ TNK/ABCX. b Denotes P for comparison between TNK/ENOX and ½ TNK/ABCX. rt-pa versus that achieved with conventional rt-pa and unfractionated heparin. 5 The relationship between clinical end-points and ST resolution at 180 min (Table 2b) is particularly instructive as it relates to potential insights into the differential mechanisms of benefit of the two experimental ASSENT 3 treatment strategies. Whereas combination therapy with TNK/ABCX achieved earlier and more complete ST resolution that appeared to closely mirror enhanced clinical efficacy in ASSENT 3, this was not the case at 60 min for TNK/ENOX. Although at 180 min a treatment effect with TNK/ENOX on ST resolution became more evident, it was virtually identical to that achieved with TNK/ unfractionated heparin. Indeed, one of the most striking effects of TNK/ENOX was on the pronounced reduction in reinfarction amongst those patients with complete ST resolution by 180 min as compared with TNK/UH. This finding is also supported by prior angiographic findings in HART-2 indicating a strong trend towards reduced reocclusion with combination enoxaparin and rt-pa versus unfractionated heparin and rt-pa in those patients achieving early coronary patency. 5 Also noteworthy was
8 1522 P.W. Armstrong et al. the striking effect of TNK/ENOX on reducing reinfarction amongst those with complete ST resolution by 180 min vs those in the same treatment arm with no ST resolution at this juncture: thereby emphasizing that once reperfusion occurs with this regimen it has a greater likelihood of being sustained than when achieved with other treatment regimens. Hence, our observations derived from a large cohort of systematically studied patients highlight two different and potentially complementary pharmacologic reperfusion regimens applied to the management of patients with acute ST segment myocardial infarction. Although our study excluded 1791 patients with incomplete electrocardiographic information whose mortality was higher (Fig. 1), the comparability of baseline characteristics within the three treatment groups in the ECG study, and the close alignment of these outcomes with those demonstrated in the overall study, provides substantial reassurance about the relevance of our findings. Additionally, a small number of patients (n=296, 17%) underwent urgent PCI in the ECG substudy within the first hospital day: although we cannot establish with certainty the timing of these procedures, it is unlikely they occurred between the two ECG points of 60 and 180 min and therefore would not be expected to have significant impact on our results. Nonetheless, given the moderate sample sizes once categorization of outcomes was divided into the three different treatment regimens and ST segment resolution categories, there is need for caution in interpreting these comparisons and we cannot be assured of a direct causal relationship to outcomes. The impressive additional improvement in complete ST resolution that occurs between 60 and 180 min raises questions about the optimal time to assess the success or failure of pharmacologic reperfusion of acute myocardial infarction and the potential added value of cointervention with mechanical revascularization within this interval for such patients. The consistently excellent outcome of patients with complete ST resolution at 180 min, irrespective of which treatment regimen was employed, provides impetus for further investigation of this issue. In particular, the evaluation of enhanced early reperfusion with the addition of a glycoprotein IIb/IIIa inhibitor coupled with the potential for reduced reinfarction and presumable reocclusion with low molecular weight heparin and fibrinolytic therapy seems provided safety concerns can be addressed a worthwhile pursuit. 6,7 Acknowledgements It is a pleasure to acknowledge the significant contribution and participation of the ECG readers from the three Core Laboratories who participated in this study: Pushpa Jagasia, Norma Hill, Quamrul Hassan, Janna Luchansky, and the coordinating assistance of Soetkin Vlassak, André Beernaert, Shirley Bestilny, Kathy Shuping and the editorial assistance of Lynne Calder. The study was supported by Boehringer Ingelheim, Germany; Genentech, South San Francisco, CA, USA; and Aventis, Bridgewater, NJ, USA. References 1. ASSENT 3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab or unfractionated heparin: the ASSENT 3 randomized trial of acute myocardial infarction. Lancet 2001;358: Schroder R, Wegscheider K, Schroder K et al., for the INJECT trial group. Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. JAmColl Cardiol 1995;26: Shah A, Wagner GS, Granger CB et al. Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST segment resolution analysis. J Am Coll Cardiol 2000; 35: Fu Y, Goodman S, Chang W-C et al. for the ASSENT 2 Investigators. Time to treatment influences the impact of ST segment resolution on one-year prognosis: Insights from ASSENT 2. Circulation 2001; 104: Ross AM, Molhoek P, Lundergan C et al. A randomized comparison of low molecular weight heparin, enoxaparin and unfractionated heparin adjunctive to tpa thrombolysis in aspirin (HART-II). Circulation 2001; 104: GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;57: Antman EM, Louwerenburg HW, Baars HF et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 trial. Circulationr 2002;105:r27 34.
The restoration of coronary flow after an
Pharmacological Reperfusion in Acute Myicardial Infarction after ASSENT 3 and GUSTO V [81] DANIEL FERREIRA, MD, FESC Serviço de Cardiologia, Hospital Fernando Fonseca, Amadora, Portugal Rev Port Cardiol
More informationCurrent Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach
Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach Frans Van de Werf, MD, PhD University Hospitals, Leuven, Belgium Frans Van de Werf: Disclosures Research grants
More informationResearch. Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data
Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT- and - PLUS data Paul W. Armstrong, Wei-Ching Chang, Lars Wallentin, Patrick Goldstein, Christopher B. Granger,
More informationInter-regional differences and outcome in unstable angina
European Heart Journal (2000) 21, 1433 1439 doi:10.1053/euhj.1999.1983, available online at http://www.idealibrary.com on Inter-regional differences and outcome in unstable angina Analysis of the International
More informationPHARMACO-INVASIVE STRATEGY COMPARED WITH PPCI: DESIGN AND MAIN OUTCOMES OF THE STREAM TRIAL
PHARMACO-INVASIVE STRATEGY COMPARED WITH PPCI: DESIGN AND MAIN OUTCOMES OF THE STREAM TRIAL Frans Van de Werf Leuven, Belgium Disclosures Study grant from Boehringer Ingelheim to perform the STREAM trial,
More informationThrombolytic effect of streptokinase infusion assessed by ST-segment resolution between diabetic and non-diabetic myocardial infarction patients
ORIGINAL ARTICLE Cardiology Journal 2012, Vol. 19, No. 2, pp. 168 173 10.5603/CJ.2012.0029 Copyright 2012 Via Medica ISSN 1897 5593 Thrombolytic effect of streptokinase infusion assessed by ST-segment
More informationThe Strategic Reperfusion Early After STEMI study Implications for clinical practice
The Strategic Reperfusion Early After STEMI study Implications for clinical practice Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization and Interventional
More informationRisk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium
Risk Stratification of ACS Patients Frans Van de Werf, MD, PhD University of Leuven, Belgium Which type of ACS patients are we talking about to day? 4/14/2011 STEMI and NSTEMI in the NRMI registry from
More informationImproving the Outcomes of
Improving the Outcomes of STEMI Shelley Valaire, ACP; and Robert Welsh, MD, FRCPC Presented at the University of Alberta s 6th Annual Cardiology Update for General Practitioners and Internists, Edmonton,
More informationEarly release, published at on April 30, Subject to revision.
CMAJ Early release, published at www.cmaj.ca on April 30, 2012. Subject to revision. Research Baseline as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial Hany
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationManagement of Acute Myocardial Infarction
Management of Acute Myocardial Infarction Prof. Hossam Kandil Professor of Cardiology Cairo University ST Elevation Acute Myocardial Infarction Aims Of Management Emergency care (Pre-hospital) Early care
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationClinical Cardiology Prognostic Significance of the Initial Electrocardiogram in Patients With Acute Myocardial Infarction
Clinical Cardiology Prognostic Significance of the Initial Electrocardiogram in Patients With Acute Myocardial Infarction William R. Hathaway, MD; Eric D. Peterson, MD, MPH; Galen S. Wagner, MD; Christopher
More informationMyocardial Infarction In Dr.Yahya Kiwan
Myocardial Infarction In 2007 Dr.Yahya Kiwan New Definition Of Acute Myocardial Infarction The term of myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting
More informationJournal of the American College of Cardiology Vol. 41, No. 3, by the American College of Cardiology Foundation ISSN /03/$30.
Journal of the American College of Cardiology Vol. 41, No. 3, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02824-3
More informationThrombolysis in Acute Myocardial Infarction
CHAPTER 70 Thrombolysis in Acute Myocardial Infarction J. S. Hiremath Introduction Reperfusion of the occluded coronary artery at the earliest is the most important aim of management of STEMI. Once a flow
More informationIntraluminal Thrombus in Facilitated Versus Primary Percutaneous Coronary Intervention
Journal of the American College of Cardiology Vol. 57, No. 19, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.061
More informationThe First 12 Hours. ST-Segment Elevation AMI: Introduction. Definitions
ST-Segment Elevation AMI: The First 12 Hours Acute myocardial infarction (AMI) accounts for half of the deaths due to ischemic heart disease and is associated with significant use of resources. Because
More informationReperfusion therapy for ST-segment elevation myocardial infarction: a review of the available treatment options in Kuwait
Reperfusion therapy for ST-segment elevation myocardial infarction: a review of the available treatment options in Kuwait Mohammad Zubaid 1, Wafa A. Rashed 2, Mustafa Ridha 3 CME Acute myocardial infarction
More informationSimon Horne 1 Clive Weston 2 * Tom Quinn 3 Anne Hicks 4 Lynne Walker 5 Ruoling Chen 6 John Birkhead 5
The impact of pre-hospital thrombolytic treatment on re-infarction rates: analysis of the Myocardial Infarction National Audit Project (MINAP). Simon Horne 1 Clive Weston 2 * Tom Quinn 3 Anne Hicks 4 Lynne
More informationFacilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?
Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction Is it beneficial to patients? Seung-Jea Tahk, MD. PhD. Suwon, Korea Facilitated PCI.. background Degree of coronary flow at
More informationHeart Online First, published on October 26, 2005 as /hrt
Heart Online First, published on October 26, 2005 as 10.1136/hrt.2005.072975 1 Admission NT-proBNP and it s interaction with admission Troponin T and ST-segment resolution for early risk stratification
More informationSTREAM - ONE YEAR MORTALITY STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION. STREAM 1Y AHA 2013 P Sinnaeve
STREAM - ONE YEAR MORTALITY STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION PCI Hospital Ambulance/ER STREAM design STEMI
More information30-day mortality (odds ratio 2.2, p = 0.045). CLC is independently associated with indexes of poorer epicardial flow and a higher incidence of adverse
Am J Cardiol (2005);95:383-6 Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction
More informationPharmaco-Invasive Approach for STEMI
Pharmaco-Invasive Approach for STEMI Michael C. Kontos, MD Medical Director, Coronary Intensive Care Unit Director, Chest Pain Evaluation Center Associate Professor Departments of Internal Medicine (Cardiology),
More informationSHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI?
SHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI? Kurt Huber, MD 3 Department of Internal Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria Disclosures DISCLOSURE
More informationSTEMI Care 2014 at the Crossroads: Taking the right road
STEMI Care 2014 at the Crossroads: Taking the right road Robert C. Welsh, MD, FRCPC, FESC, FAHA, FACC Professor of Medicine Vice President, The Canadian Association of Interventional Cardiology Director,
More informationI n patients with acute ST elevation myocardial infarction
1400 CARDIOVASCULAR MEDICINE Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trial R C Welsh, W Chang,
More informationST Elevation Myocardial Infarction (STEMI) Reperfusion Order Set
Form Title Form Number CH-0454 2018, Alberta Health Services, CKCM This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. The license does not
More informationIN patients with ST elevated myocardial infarction, ST segment resolution following
The Effect of Tirofiban on ST Segment Resolution in Patients With Non-ST Elevated Myocardial Infarction Özgür BAYTURAN, 1 MD, Ali Riza BILGE, 1 MD, Cevad SEKÜRI, 1 MD, Ozan ÜTÜK, 1 MD, Hakan TIKIZ, 1 MD,
More informationORIGINAL ARTICLE. Rescue PCI Versus a Conservative Approach for Failed Fibrinolysis in Patients with STEMI
Heart Mirror Journal From Affiliated Egyptian Universities and Cardiology Centers Vol. 6, No. 3, 2012 ISSN 1687-6652 ORIGINAL ARTICLE for Failed Fibrinolysis in Patients with STEMI Mohamed Salem, MD, PhD;
More informationJournal of the American College of Cardiology Vol. 39, No. 11, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 39, No. 11, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01856-9
More informationThrombolysis, adjunctive pharmacology and interventions
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation ESC Annual Congress Munich, 2012 Thrombolysis, adjunctive pharmacology and interventions
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 26 June 2003 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER ON THE CLINICAL
More informationMedical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI
Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist physician Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI Outcome objectives of the discussion: At the end of the
More informationChapter 3. Departments of a Cardiology and b Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands; c
Chapter 3 Incidence, patient s characteristics and predictors of aborted myocardial infarction in patients undergoing primary PCI: prospective study comparing pre- and in-hospital abciximab pretreatment
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationJournal of the American College of Cardiology Vol. 41, No. 6, by the American College of Cardiology Foundation ISSN /03/$30.
Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02970-4
More informationCritical Review Form Therapy Objectives: Methods:
Critical Review Form Therapy Clinical Trial Comparing Primary Coronary Angioplasty with Tissue-Plasminogen Activator for Acute Myocardial Infarction (GUSTO-IIb), NEJM 1997; 336: 1621-1628 Objectives: To
More informationThe Window for Fibrinolysis. Frans Van de Werf, MD, PhD Leuven, Belgium
The Window for Fibrinolysis Frans Van de Werf, MD, PhD Leuven, Belgium ESC STEMI Guidelines : December 2008 Reperfusion Therapy: Fibrinolytic Therapy Recommendations Class LOE In the absence of contraindications
More informationA Report From the Second National Registry of Myocardial Infarction (NRMI-2)
1240 JACC Vol. 31, No. 6 Clinical Experience With Primary Percutaneous Transluminal Coronary Angioplasty Compared With Alteplase (Recombinant Tissue-Type Plasminogen Activator) in Patients With Acute Myocardial
More informationAnnie Chou Internal Medicine PGY3 University of British Columbia. Rocky Mountain Internal Medicine Conference November 24, 2011
Annie Chou Internal Medicine PGY3 University of British Columbia Rocky Mountain Internal Medicine Conference November 24, 2011 Role of the ECG in STEMI Diagnosis of myocardial infarction Localization of
More informationDISCUSSION QUESTION - 1
CASE PRESENTATION 87 year old male No past history of diabetes, HTN, dyslipidemia or smoking Very active Medications: omeprazole for heart burn Admitted because of increasing retrosternal chest pressure
More informationJournal of the American College of Cardiology Vol. 37, No. 4, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 4, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01143-3 Acute
More informationLong-Term Prognostic Value of ST-Segment Resolution in Patients Treated With Fibrinolysis or Primary Percutaneous Coronary Intervention
Journal of the American College of Cardiology Vol. 54, No. 19, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.03.084
More informationTICAGRELOR VERSUS CLOPIDOGREL AFTER THROMBOLYTIC THERAPY IN PATIENTS WITH ST- ELEVATION MYOCARDIAL INFARCTION: A RANDOMIZED CLINICAL TRIAL
TICAGRELOR VERSUS CLOPIDOGREL AFTER THROMBOLYTIC THERAPY IN PATIENTS WITH ST- ELEVATION MYOCARDIAL INFARCTION: A RANDOMIZED CLINICAL TRIAL Otavio Berwanger, MD, PhD - On behalf of the TREAT Trial Steering
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial
compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial Outcomes in patients with and planned PCI Ph.Gabriel Steg*, Stefan James, Robert A
More informationRandomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction
Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction The Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4
More informationJACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 5, PUBLISHED BY ELSEVIER INC. DOI: /j.jcin
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 5, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2008.06.009 Reduced-Dose
More informationClopidogrel Date: 15 July 2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary
More informationJun Dong. Prüfer der Dissertation: 1. apl. Prof. Dr. C. G. Schmitt. 2. Univ.-Prof. A. Kastrati. 3. Univ.-Prof. Dr. Dr. R. Senekowitsch-Schmidtke
Deutsches Herzzentrum München des Freistaates Bayern Klinik an der Technischen Universität München Klinik für Herz-und Kreislauferkrankungen (Direktor: Univ.-Prof. Dr. A. Schömig) Extent of Early ST-Segment
More informationStatistical analysis plan
Statistical analysis plan Prepared and approved for the BIOMArCS 2 glucose trial by Prof. Dr. Eric Boersma Dr. Victor Umans Dr. Jan Hein Cornel Maarten de Mulder Statistical analysis plan - BIOMArCS 2
More informationContinuing Medical Education Post-Test
Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on
More informationTRANSPARENCY COMMITTEE OPINION. 2 April 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 April 2008 LOVENOX 6,000 IU anti-xa/0.6 ml, injectable solution (S.C.) in prefilled syringe Box of 2 (CIP: 364 690-3)
More informationAPPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
More informationThe Need for Rescue PCI after Failed Fibrinolysis: Who, When and Why.
Implementing the pharmacoinvasive strategy in STEMI The Need for Rescue PCI after Failed Fibrinolysis: Who, When and Why. 7:20-7:40 Robert C. Welsh, MD, FRCPC, FESC, FAHA, FACC Professor of Medicine Director,
More informationMode of admission and its effect on quality indicators in Belgian STEMI patients
2015 Mode of admission and its effect on quality indicators in Belgian STEMI patients Prof dr M Claeys National Coordinator STEMI registry 29-6-2015 Background The current guidelines for the management
More informationCardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.
Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:
More informationAcute myocardial infarction. Cardiovascular disorders. main/0202_new 02/03/06. Search date August 2004 Nicholas Danchin and Eric Durand
main/0202_new 02/03/06 Acute myocardial infarction Search date August 2004 Nicholas Danchin and Eric Durand QUESTIONS Which treatments improve outcomes in acute myocardial infarction?...4 Which treatments
More informationC h a p t e r 3 Acute Myocardial Infarction - Management in First 3 Hours
C h a p t e r 3 Acute Myocardial Infarction - Management in First 3 Hours AB Mehta 1 BP Shivdasani 2 1 Director of Cardiology, Jaslok Hospital, Mumbai. 2 Clinical Associate, Jaslok Hospital, Mumbai. Introduction
More informationPlatelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes
European Heart Journal (00) 3, 1441 1448 doi:10.1053/euhj.00.3160, available online at http://www.idealibrary.com on Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes Gradient of benefit
More informationTIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS
European Heart Journal (2005) 26, 865 872 doi:10.1093/eurheartj/ehi187 Clinical research TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationCombined Angioplasty and Pharmacological Intervention Versus Thrombolysis Alone in Acute Myocardial Infarction (CAPITAL AMI Study)
Journal of the American College of Cardiology Vol. 46, No. 3, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.04.042
More informationUPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME. DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18
UPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18 INTRODUCTION The clinical entities that comprise acute coronary syndromes (ACS)-ST-segment
More informationTenecteplase: Innovative Fibrinolysis for ST-Segment Elevation Myocardial Infarction (STEMI)
Tenecteplase: Innovative Fibrinolysis for ST-Segment Elevation Myocardial Infarction (STEMI) Gordon J. Vanscoy, PharmD, CACP, MBA, Thomas L. Rihn, PharmD, and Pamela H. Koerner, PharmD ABSTRACT The use
More informationLack of progress in cardiogenic shock: lessons from the GUSTO trials
European Heart Journal (2000) 21, 1928 1936 doi:10.1053/euhj.2000.2240, available online at http://www.idealibrary.com on Lack of progress in cardiogenic shock: lessons from the GUSTO trials V. Menon 1,
More informationSTEMI 2014 YAHYA KIWAN. Consultant Cardiologist Head Of Cardiology Belhoul Specialty Hospital
STEMI 2014 YAHYA KIWAN Consultant Cardiologist Head Of Cardiology Belhoul Specialty Hospital Aspiration Thrombectomy Manual aspiration thrombectomy is reasonable for patients undergoing primary PCI. I
More informationStress ECG is still Viable in Suleiman M Kharabsheh, MD, FACC Consultant Invasive Cardiologist KFHI KFSHRC-Riyadh
Stress ECG is still Viable in 2016 Suleiman M Kharabsheh, MD, FACC Consultant Invasive Cardiologist KFHI KFSHRC-Riyadh Stress ECG Do we still need stress ECG with all the advances we have in the CV field?
More informationPost-Reteplase Evaluation of Clinical Safety & Efficacy in Indian Patients (Precise-In Study)
30 Post-Reteplase Evaluation of Clinical Safety & Efficacy in Indian Patients (Precise-In Study) RK Singh 1, A Trailokya 2, MM Naik 3 Original Article Abstract Background: ST elevated myocardial infarction
More informationPrimary PCI versus thrombolytic therapy: long-term follow-up according to infarct location
Heart Online First, published on April 14, 2005 as 10.1136/hrt.2005.060152 1 Primary PCI versus thrombolytic therapy: long-term follow-up according to infarct location Short running head: Anterior infarction
More informationRelationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João
More informationHot Topics in Cardiac Arrest. Should the patient go To the Cath Lab?
Hot Topics in Cardiac Arrest Should the patient go To the Cath Lab? Tim Russert 1950-2008 Host of NBC s Meet the Press Sudden Cardiac Arrest : Autopsy showed plaque rupture in his LAD ( per LA Times,
More informationSignificance of QRS duration in non-st elevation myocardial infarction.
Thomas Jefferson University Jefferson Digital Commons Cardiology Faculty Papers Department of Cardiology 5-6-2015 Significance of QRS duration in non-st elevation myocardial infarction. Chinualumogu Nwakile
More informationSerum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction
Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction Masahisa Shimpo, MD, PhD; David A. Morrow, MD, MPH; Ellen O. Weinberg,
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationReview The Use of Low Molecular Weight Heparins and Platelet GP IIb/IIIa Inhibitors as Adjuncts to Thrombolysis: Are there any Perspectives?
Hellenic J Cardiol 45: 312-323, 2004 Review The Use of Low Molecular Weight Heparins and Platelet GP IIb/IIIa Inhibitors as Adjuncts to Thrombolysis: Are there any Perspectives? DIMITRA D. KONTOGIANNI,
More informationMethods Individual patient data from CAPTIM (n = 840, ) and the more recent WEST trial (n = 328, ) were pooled.
The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: A pooled analysis of an early fibrinolytic strategy versus primary percutaneous
More informationThe FRISC II ECG substudy
European Heart Journal (22) 23, 41 49 doi:1.153/euhj.21.2694, available online at http://www.idealibrary.com on ST depression in ECG at entry indicates severe coronary lesions and large benefits of an
More informationDiagnosis of Myocardial Infarction/Ischemia with Bundle Branch Blocks
Diagnosis of Myocardial Infarction/Ischemia with Bundle Branch Blocks Mark I. Langdorf, MD, MHPE, FACEP, FAAEM, RDMS Professor and Chair Associate Residency Director Department of Emergency Medicine University
More informationPexelizumab and Infarct Size in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
JACC: CARDIOVASCULAR IMAGING VOL. 3, NO. 1, 2010 2010 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-878X/10/$36.00 PUBLISHED BY ELSEVIER INC. DOI:10.1016/j.jcmg.2009.09.014 Pexelizumab and
More informationPRIMARY CORONARY ANGIOPLASTY VERSUS INTRAVENOUS THROMBOLYSIS FOR ACUTE MYOCARDIAL INFARCTION - A COMPARATIVE STUDY AT QUEEN ALIA HEART INSTITUTE
PRIMARY CORONARY ANGIOPLASTY VERSUS INTRAVENOUS THROMBOLYSIS FOR ACUTE MYOCARDIAL INFARCTION - A COMPARATIVE STUDY AT QUEEN ALIA HEART INSTITUTE Walid Sawalha MD, MBBS (Lond), MRCP(UK)* ABSTRACT Objectives:
More informationMANAGEMENT (Table 9.1) The choice of treatment for ACS largely depends on an assessment of the risk of immediate extensive myocardial
242 INTENSIVE CARE a I II III AVR AVL AVF V 1 V 2 V 3 V 4 V 5 V 6 Fig. 9.1 Electrocardiogram (ECG) changes in myocardial infarction and evolution of ECG changes in ST-segment elevation myocardial infarction
More informationFrom the a Stockholm South Hospital, Stockholm, Sweden,
Comparison of very early treatment with either fibrinolysis or percutaneous coronary intervention facilitated with abciximab with respect to ST recovery and infarct-related artery epicardial flow in patients
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationTHE ECONOMICS OF ADJUNCTIVE THERAPIES IN CORONARY ANGIOPLASTY: DRUGS, DEVICES, OR BOTH?
THE ECONOMICS OF ADJUNCTIVE THERAPIES IN CORONARY ANGIOPLASTY: DRUGS, DEVICES, OR BOTH? Paul I. Oh, 1 Eric A. Cohen, 2 Nicole Mittmann, 3, 4 Soo Jin Seung 4 1 Division of Clinical Pharmacology, Sunnybrook
More informationbivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company
bivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company 06 August 2010 The Scottish Medicines Consortium (SMC) has completed its
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life
More informationThe organisation of troponin testing services in acute coronary syndromes
Health Technology Assessment Advice 4 ~ December 2003 The organisation of troponin testing services in acute coronary syndromes Summary of recommendations NHS Quality Improvement Scotland recommends that
More informationI. Admission Troponin T and measurement of ST-segment resolution at 60 minutes improve early risk stratification in ST-elevation myocardial
LIST OF PAPERS I. Admission Troponin T and measurement of ST-segment resolution at 60 minutes improve early risk stratification in ST-elevation myocardial infarction. Björklund E, Lindahl B, Johanson P,
More informationSTEMI: Newer Aspects in Pharmacological Treatment
CHAPTER 14 STEMI: Newer Aspects in Pharmacological Treatment P. C. Manoria, Pankaj Manoria Introduction ST elevation myocardial infarction (STEMI) commonly results from disruption of a vulnerable plaque
More informationPCI Strategies After Fibrinolytic Therapy
PCI Strategies After Fibrinolytic Therapy How to choose the appropriate reperfusion strategy. BY MICHEL R. LE MAY, MD Survival in patients presenting with ST-segment elevation myocardial infarction (STEMI)
More informationThrombolysis in Cardiology to whom? Professor Steen D. Kristensen, MD, DMSc, FESC Department of Cardiology
Thrombolysis in Cardiology to whom? Professor Steen D. Kristensen, MD, DMSc, FESC Department of Cardiology UNIVERSITY OF AARHUS 1 COI Speakers fee: Aspen, AZ, Bayer, BMS/Pfizer Departmental research grant:
More informationWith the emergence of prehospital care for ST-segment
Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction? Jay Shavadia, MD; Yinggan Zheng, MA, MEd; Neda Dianati
More informationAcute ST-segment elevation myocardial infarction (MI)
Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Venu Menon, MD; Robert A. Harrington, MD; Judith S. Hochman, MD;
More informationHyang Ki Min, Ji Young Park, Jae Woong Choi, Sung Kee Ryu, Seunghwan Kim, Chang Sup Song, Dong Shin Kim, Chi Woo Song, Se Jong Kim, Young Bin Kim
ORIGINAL ARTICLE eissn 2384-0293 Yeungnam Univ J Med 2017;34(2):191-199 https://doi.org/10.12701/yujm.2017.34.2.191 Long-term clinical outcome of acute myocardial infarction according to the early revascularization
More informationUtilization and Impact of Pre-Hospital Electrocardiograms for Patients With Acute ST-Segment Elevation Myocardial Infarction
Journal of the American College of Cardiology Vol. 53, No. 2, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.09.030
More informationAndreas Baumbach Bristol Heart Institute Bristol Royal Infirmary. London 27/1/2005
Andreas Baumbach Bristol Heart Institute Bristol Royal Infirmary AB London 27/1/2005 Revascularisation in ACS ICTUS MERLIN REACT 4mins 4mins 4mins AB Tony s Comments 15mins ICTUS Comparison of an early
More information